Skip to content
Meta-analysis Open access

Comparative safety of the 20-valent and the 13-valent pneumococcal vaccines in infants and toddlers: a systematic review and meta-analysis of randomized trials

Nov 2026 · Revista Paulista de Pediatria · Vol 44 · 0 citations · 28 references
Medicine

Abstract

ABSTRACT Objective: This systematic review and meta-analysis aimed to compare the safety of the 20-valent pneumococcal conjugate vaccine versus the 13-valent pneumococcal vaccine in healthy infants and toddlers. Data source: We searched PubMed, Scopus, Embase, and Cochrane on January 20, 2026, for randomized controlled trials comparing the 20-valent pneumococcal conjugate vaccine with the 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers (0-3 years). We computed risk ratios with 95% confidence intervals for all outcomes, using a random-effects model. Heterogeneity was assessed using I2 statistics. Data synthesis: Five randomized clinical trials were included, comprising 5,604 patients, of whom 3,059 received the 20-valent pneumococcal conjugate vaccine. There were no significant differences between the 20-valent pneumococcal conjugate vaccine and the 13-valent pneumococcal conjugate vaccine in adverse event incidence after doses 1-3 (risk ratio 1.00; 95%CI 0.92–1.10; p=0.952; I2=0%), or after dose 4 (risk ratio 0.90; 95%CI 0.76–1.07; p=0.238; I2=36%). Similarly, no significant differences were observed in serious adverse events, fever, irritability, and injection site pain. The 20-valent pneumococcal conjugate vaccine was associated with a higher incidence of decreased appetite after doses 2 (risk ratio 1.13, 95%CI 1.02–1.24; p=0.019) and 3 (risk ratio 1.34, 95%CI 1.14–1.58; p<0.001). In contrast, a significantly lower risk of local redness was observed with the 20-valent pneumococcal conjugate vaccine after dose 2 (risk ratio 0.93; 95%CI 0.86–0.99; p=0.034). Conclusions: The 20-valent pneumococcal conjugate vaccine demonstrated a safety profile largely comparable to the 13-valent pneumococcal conjugate vaccine, supporting its use in routine pediatric immunization programs.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.